Collegium Pharmaceutical, Inc. (COLL)

Several events impacted Collegium Pharmaceutical, Inc.'s stock price over the past six months. Collegium reported strong third-quarter 2025 financial results, leading to raised full-year 2025 guidance. An analysis suggested Collegium was undervalued, with potential for significant total shareholder return. The company reported strong fourth-quarter and full-year 2025 financial results. Collegium announced a campaign with Paris Hilton for JORNAY PM. Collegium announced its acquisition of AZSTARYS® from Corium Therapeutics. Collegium announced participation in upcoming investor conferences.

Demand seasonality for Collegium Pharmaceutical's products is evident, particularly for its ADHD medication, Jornay PM. The company anticipates a strong "back-to-school" season and second half of the year for Jornay PM, leading to increased revenue guidance. The consistent growth in the pain portfolio throughout the year suggests a more stable demand profile.

Collegium Pharmaceutical, Inc. is a biopharmaceutical company focused on improving the lives of individuals with serious medical conditions. The company operates in the pharmaceuticals sector, focusing on pain management and neuropsychiatry, particularly ADHD. Collegium develops, licenses, and acquires a portfolio of differentiated medications, including Jornay PM for ADHD, Belbuca for severe pain, Xtampza ER for moderate to severe pain, Nucynta ER/IR for severe and acute pain, and Symproic for opioid-induced constipation.

Collegium Pharmaceutical, Inc. primarily commercializes its products in the United States and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical aims to maintain a positive reputation by focusing on responsible pain management and improving the lives of people with serious medical conditions. Collegium was dismissed from opioid-related litigation, which is a positive for its reputation. The company's products like Xtampza ER are designed with abuse-deterrent properties, which contributes positively to its reputation. The acquisition of Jornay PM and the agreement to acquire AZSTARYS® demonstrate a strategic diversification into neuropsychiatry, specifically ADHD. Collegium has presented new real-world data at conferences and published studies highlighting the benefits of its treatments.

Institutional ownership dominates Collegium Pharmaceutical's ownership structure, with 274 institutional owners and shareholders holding a total of 35,926,959 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Eventide Asset Management, Llc. The largest individual shareholder is David Hirsch, owning 6,438,798 shares, representing 20.28% of the company. Insider ownership collectively holds low-single-digit percentages.